Global Blood Therapeutics (NASDAQ:GBT) Research Coverage Started at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Global Blood Therapeutics (NASDAQ:GBTGet Rating) in a report released on Monday. The firm set a “hold” rating on the stock.

Several other brokerages also recently weighed in on GBT. Canaccord Genuity Group raised shares of Global Blood Therapeutics from a “hold” rating to a “buy” rating and boosted their target price for the company from $40.00 to $72.00 in a research note on Monday, August 8th. Cowen cut Global Blood Therapeutics to a “market perform” rating and increased their target price for the company from $67.00 to $68.50 in a research note on Tuesday, August 9th. William Blair cut Global Blood Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, August 8th. Wedbush cut Global Blood Therapeutics to a “neutral” rating in a research note on Monday, August 15th. Finally, SVB Leerink lowered Global Blood Therapeutics from an “outperform” rating to a “market perform” rating and set a $68.50 target price on the stock. in a research report on Tuesday, August 9th. Twelve equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Global Blood Therapeutics presently has an average rating of “Hold” and a consensus target price of $65.42.

Global Blood Therapeutics Price Performance

Shares of NASDAQ GBT opened at $68.49 on Monday. Global Blood Therapeutics has a one year low of $21.65 and a one year high of $73.02. The company has a debt-to-equity ratio of 4.92, a quick ratio of 6.17 and a current ratio of 6.88. The company’s fifty day moving average is $68.32 and its two-hundred day moving average is $49.91. The firm has a market capitalization of $4.62 billion, a P/E ratio of -13.67 and a beta of 0.45.

Institutional Investors Weigh In On Global Blood Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SkyView Investment Advisors LLC boosted its position in shares of Global Blood Therapeutics by 587.2% during the first quarter. SkyView Investment Advisors LLC now owns 804 shares of the company’s stock worth $28,000 after buying an additional 687 shares during the period. Longfellow Investment Management Co. LLC acquired a new position in Global Blood Therapeutics during the third quarter valued at approximately $36,000. China Universal Asset Management Co. Ltd. acquired a new position in Global Blood Therapeutics during the third quarter valued at approximately $43,000. Nisa Investment Advisors LLC raised its stake in Global Blood Therapeutics by 75.6% in the first quarter. Nisa Investment Advisors LLC now owns 1,510 shares of the company’s stock valued at $52,000 after buying an additional 650 shares during the period. Finally, Lazard Asset Management LLC bought a new stake in Global Blood Therapeutics in the third quarter valued at approximately $123,000.

Global Blood Therapeutics Company Profile

(Get Rating)

Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.

Featured Stories

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.